You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 18, November 9, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Pregnancy and Breast Feeding
 •Pediatrics
 •Neonatology and Infant Care
 •Alert me on articles by topic

Neonatal Signs After In Utero Exposure to Selective Serotonin Reuptake Inhibitors—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: We appreciate the distinction between the timing of the SSRI-associated neonatal behavioral syndrome and that of infantile colic made by Dr Kaye and Ms Weinstein. We made this analogy because of the commonality of signs that comprise the SSRI-associated neonatal behavioral syndrome and colic (irritability and crying). Our intention was to place the SSRI-associated neonatal behavioral syndrome in the context of other mild, non–life-threatening syndromes that are familiar to a general audience. The statement that pregnant women should not discontinue their SSRIs to prevent colic or blame themselves for causing colic is a very important contribution to this discussion.

We were interested to learn from Dr Lavenstein of an additional 3 cases that follow the pattern and support the self-limited nature of the SSRI-associated neonatal behavioral syndrome described in our review. We would like to clarify that late-gestational fluoxetine, because of its long half-life, is likely to lead . . . [Full Text of this Article]

Eydie L. Moses-Kolko, MD
mosesel@upmc.edu

Debra Bogen, MD; James Perel, PhD; Katherine L. Wisner, MD, MS
University of Pittsburgh School of Medicine
Pittsburgh, Pa

Amy Bregar
Princeton University
Princeton, NJ

Kathleen Uhl, MD; Bob Levin, MD
Center for Drug Evaluation and Research
US Food and Drug Administration
Rockville, Md


RELATED ARTICLES

Neonatal Signs After In Utero Exposure to Selective Serotonin Reuptake Inhibitors
Bennett A. Kaye and Judith Weinstein
JAMA. 2005;294(18):2299-2300.
EXTRACT | FULL TEXT  

Neonatal Signs After In Utero Exposure to Selective Serotonin Reuptake Inhibitors
Bennett Lavenstein
JAMA. 2005;294(18):2300.
EXTRACT | FULL TEXT  

Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors: Literature Review and Implications for Clinical Applications
Eydie L. Moses-Kolko, Debra Bogen, James Perel, Amy Bregar, Kathleen Uhl, Bob Levin, and Katherine L. Wisner
JAMA. 2005;293(19):2372-2383.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.